Table 2 Changes in serum liver test during the administration of sequences A and B in three different times. Comparation in serum liver tests during the administration of sequences A and B in three different times (T0, T1 and T2). There were no significant changes in the test results, indicating that there are no differences between the drugs. These results showed the therapeutic efficacy of the drug manufactured in capsules and tablets relative to the standard drug.
Laboratory parameters | Sequence A Tablets= > Capsules (n = 15) | Sequence B Capsules= > Tablets (n = 15) | P value | ||||
|---|---|---|---|---|---|---|---|
T0 | T1 | T2 | T0 | T1 | T2 | ||
Alkaline phosphatase (U/L) | 155.20 ± 120.03 | 149.30 ± 90.83 | 156.40 ± 110.15 | 97.00 ± 31.31 | 105.27 ± 49.06 | 101.20 ± 31.79 | 0.888 |
Gamma glutamyl transferase (U/L) | 95.13 ± 126.14 | 95.47 ± 121.81 | 96.07 ± 120.11 | 116.33 ± 113.13 | 136.67 ± 162.93 | 117.33 ± 118.11 | 0.579 |
Alanine aminotransferase (U/L) | 32.00 ± 31.33 | 33.93 ± 39.06 | 35.13 ± 40.23 | 39.57 ± 21.15 | 35.07 ± 17.94 | 53.53 ± 75.89 | 0.579 |
Aspartate aminotransferase (U/L) | 31.33 ± 21.07 | 31.93 ± 22.75 | 32.87 ± 21.55 | 36.51 ± 14.85 | 34.53 ± 10.45 | 46.53 ± 44.89 | 0.917 |
Total bilirubin (mg/dL) | 0.60 ± 0.33 | 0.63 ± 0.31 | 0.62 ± 0.35 | 0.60 ± 0.31 | 0.58 ± 0.22 | 0.56 ± 0.21 | 0.590 |